News >

PROfound Data Could Lead to First PARP Inhibitor Approval in mCRPC

Jessica Hergert
Published: Sunday, Nov 17, 2019

Alan H. Bryce, MD, an assistant professor of medicine, and chair of the Division of Hematology/Oncology, Department of Internal Medicine, Mayo Clinic,

Alan H. Bryce, MD
On the heels of the phase III PROfound trial data, Alan H. Bryce, MD, explained that interest continues to pique regarding PARP inhibitors for men with metastatic castration-resistant prostate cancer (mCRPC).
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication